
Standard Biotools (LAB) Stock
Smaller maker of lab tools for research and diagnostics. Here's the price, business snapshot, and what's worth knowing about Standard Biotools in November 2026.
Standard BioTools Inc (ticker: LAB) develops and sells instruments, reagents and software used in life‑science research and molecular diagnostics. The company’s platforms are deployed with academic researchers, pharmaceutical and biotechnology organisations and clinical laboratories. With a market capitalisation of about $504.2m, it is a smaller‑cap participant in the life‑sciences tools segment; that size can result in greater share‑price volatility and sensitivity to research and industry capital expenditure cycles. Key investment considerations include the proportion of recurring consumables revenue, the timing of instrument orders, competitive pressure from larger vendors and any regulatory matters tied to diagnostic use. Financial results can be uneven as customers delay or accelerate spending, and technology shifts can alter the competitive landscape. Investors should view this as a growth‑oriented, higher‑risk exposure within healthcare tools, review recent financials and cash flow, and seek independent advice tailored to their circumstances.
Standard Biotools (LAB) Stock Forecast
Analyst price target, next 12 months
$3.58
+469.3% vs today's $0.63
Price range over the last 12 months
Close to its 12-month low
Analysts covering Standard Biotools have a consensus 12-month target of $3.58, above the current price of $0.63.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Standard Biotools' stock, expecting it to potentially rise to $3.58.
Financial Health
Standard Biotools is performing well with steady revenue, profits, and cash flow indicators.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Growth Drivers
Recurring consumables and adoption of analytical platforms can support revenue growth, though demand may fluctuate with research funding and capital budgets.
Customer Mix
Customers include academic, biopharma and clinical labs worldwide; partnerships and institutional purchasing matter, but priorities and funding can vary.
Tech & Competition
Product innovation can create advantage, yet larger competitors and rapid technological change mean outcomes and performance can vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.